CureVac NV (CVAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.05B
Last updated: Nov 13, 2026 at 4:00 PM ET
CureVac NV (CVAC) Financials: Revenue, Profit and Cash Flow
CureVac NV reported revenue of EUR 535.18M for the fiscal year ended Dec 31, 2024, up 895.5% from the year before. That year, net income was EUR 162.19M with a net margin of 30.3%, operating cash flow was EUR 101.85M and free cash flow was EUR 83.41M. The quarter ended Sep 30, 2025 had revenue of EUR 493.90M and net income of EUR 338.04M.
Revenue and Margins
The operating margin was 33.2% in the fiscal year ended Dec 2024. Over the 6 years to Dec 2024, revenue grew from EUR 12.87M, a compound annual rate of 86.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | 535.18M | +895.5% | 80.2% | 33.2% | 30.3% |
| Dec 2023 | 53.76M | -20.3% | -131.3% | -510.1% | -484.0% |
| Dec 2022 | 67.42M | -34.5% | -172.9% | -370.0% | -369.4% |
| Dec 2021 | 102.99M | +110.6% | -131.3% | -400.3% | -399.8% |
| Dec 2020 | 48.90M | +180.8% | 71.0% | -253.6% | -264.0% |
| Dec 2019 | 17.42M | +35.3% | -60.7% | -571.3% | -573.5% |
| Dec 2018 | 12.87M | N/A | -37.9% | -565.8% | -553.5% |
Income Statement
In the fiscal year ended Dec 2024, net income turned positive after a loss the year before. In the quarter ended Sep 2025, net income was unchanged from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 535.18M | 53.76M | 67.42M | 102.99M | 48.90M | 17.42M | 12.87M |
| Cost of revenue | 105.83M | 124.37M | 183.99M | 238.19M | 14.17M | 27.98M | 17.74M |
| Gross profit | 429.35M | -70.61M | -116.57M | -135.21M | 34.73M | -10.57M | -4.87M |
| Research and development | 153.03M | 115.72M | 62.55M | 815.91M | 113.81M | 43.24M | 41.72M |
| Operating income | 177.68M | -274.21M | -249.46M | -412.26M | -124.00M | -99.50M | -72.82M |
| Net income | 162.19M | -260.17M | -249.03M | -411.72M | -129.07M | -99.87M | -71.24M |
| EBITDA | 209.69M | -234.09M | -209.39M | -386.49M | -123.09M | -93.90M | -69.85M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 493.90M | 1.25M | 893.00K | 14.47M | 493.90M | 14.44M | 12.37M | 22.57M | 16.48M | 7.58M | 7.13M | 11.69M |
| Gross profit | 472.97M | -968.00K | 18.00K | 12.98M | 471.97M | -26.29M | -29.32M | -31.03M | -7.80M | -18.27M | -13.51M | -68.31M |
| Operating income | 368.38M | -61.75M | -54.73M | -40.99M | 368.38M | -73.62M | -73.32M | -89.11M | -54.04M | -71.80M | -60.35M | -121.51M |
| Net income | 338.04M | -59.56M | -52.08M | -32.76M | 338.04M | -72.54M | -70.55M | -86.65M | -48.68M | -67.41M | -57.42M | -128.78M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded short-term debt of EUR 5.32M by 476.43M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Total assets | 802.83M | 788.25M | 860.47M | 1.16B | 1.51B | 130.62M | 125.66M |
| Current assets | 526.41M | 478.38M | 584.03M | 940.02M | 1.39B | 57.17M | 73.07M |
| Cash and equivalents | 481.75M | 402.45M | 495.80M | 811.46M | 1.32B | 30.68M | 21.38M |
| Total liabilities | 106.22M | 271.31M | 327.22M | 469.77M | 800.01M | 173.42M | 93.58M |
| Short-term debt | 5.32M | 5.00M | 4.98M | 3.47M | 3.23M | 2.00M | 217.00K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | 65.02M | N/A |
| Shareholder equity | 696.61M | 516.94M | 533.25M | 688.48M | 711.35M | -42.80M | 32.08M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.14B | 688.88M | 742.27M | 802.83M | 854.19M | 556.84M | 690.43M | 788.25M | 842.57M | 899.48M | 973.67M | 860.47M |
| Total liabilities | 267.39M | 102.51M | 95.58M | 106.22M | 129.49M | 180.30M | 243.52M | 271.31M | 240.30M | 250.43M | 260.27M | 327.22M |
| Cash and equivalents | 416.09M | 392.70M | 438.33M | 481.75M | 550.86M | 202.51M | 300.15M | 402.45M | 464.14M | 537.92M | 617.52M | 495.80M |
| Shareholder equity | 871.23M | 586.37M | 646.69M | 696.61M | 724.70M | 376.53M | 446.91M | 516.94M | 602.26M | 649.05M | 713.40M | 533.25M |
Cash Flow
In the fiscal year ended Dec 2024, free cash flow was 81.9% of operating cash flow.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 101.85M | -267.89M | -286.18M | -733.13M | 522.40M | -86.96M | -74.11M |
| Capital expenditures | 18.44M | 55.20M | 93.22M | 127.90M | 47.35M | 12.22M | 14.72M |
| Free cash flow | 83.41M | -323.09M | -379.40M | -861.03M | 475.05M | -99.19M | -88.83M |
| Investing cash flow | -18.44M | -55.20M | -93.50M | -127.90M | -45.27M | 28.18M | -4.26M |
| Financing cash flow | -5.11M | 230.89M | 63.17M | 344.96M | 819.83M | 67.98M | -112.00K |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 29.86M | -42.06M | -41.37M | -66.56M | 354.08M | -89.11M | -96.55M | -43.60M | -60.58M | -64.12M | -99.59M | -49.09M |
| Capital expenditures | 322.00K | 1.55M | 511.00K | 2.57M | 3.30M | 7.48M | 5.09M | 14.41M | 13.42M | 14.21M | 13.16M | 20.66M |
| Free cash flow | 29.54M | -43.62M | -41.88M | -69.13M | 350.78M | -96.60M | -101.64M | -58.01M | -74.00M | -78.32M | -112.75M | -69.75M |
Frequently Asked Questions About CVAC
What is CureVac NV's annual revenue?
CureVac NV reported revenue of EUR 535.18M for the fiscal year ended Dec 31, 2024.
How fast is CureVac NV's revenue growing?
Revenue was up 895.5% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 73.2%.
Is CureVac NV profitable?
Yes. CureVac NV reported net income of EUR 162.19M for the fiscal year ended Dec 31, 2024, with a net margin of 30.3%.
How much free cash flow does CVAC generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of EUR 101.85M minus capital expenditures of EUR 18.44M produced free cash flow of EUR 83.41M.
How much debt does CureVac NV have?
The balance sheet dated Dec 31, 2024 reported short-term debt of EUR 5.32M and cash and equivalents of EUR 481.75M.
CVAC pages: Overview, Financials